Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial

Overview publication

TitleEfficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial
DateJanuary 3rd, 2026
Issue nameThe Lancet Diabetes & Endocrinology
Issue numberv10.6 p407-417
DOI10.1016/s2213-8587(22)00077-8
AuthorsBattelino T, Bergenstal RM, Rodríguez A, Fernández Landó L, Bray R, Tong Z & Brown K
Read Read publication